Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › afatinib

afatinib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of afatinib

32 trials tracked of afatinib: 9 in phase 3 or 4 and 2 with published results. The most-cited published study has 58 citations.

32Trials tracked
9Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 7 Phase 2 9 Phase 1 6 Other / NA 8
  1. Phase 3 LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed · 58 cited
  2. Phase 3 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Completed · 10 cited
  3. Phase 4 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed
  4. Phase 4 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Completed
  5. Phase 3 ADAM-Afatinib Diarrhea Assessment and Management Completed
  6. Phase 3 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations Completed
Show 26 more trials
  1. Phase 3 An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) Completed
  2. Phase 3 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed
  3. Phase 3 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed
  4. Phase 2 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Completed
  5. Phase 2 Afatinib in NSCLC With HER2 Mutation Completed
  6. Phase 2 Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung Completed
  7. Phase 2 LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung Completed
  8. Phase 2 Trial of Afatinib in Pediatric Tumours Completed
  9. Phase 2 Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases Completed
  10. Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed
  11. Phase 2 Afatinib in NSCLC With HER2 Mutation Completed
  12. Phase 2 Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy Completed
  13. Phase 1 Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours Completed
  14. Phase 1 Drug Interaction Study With Rifampicin and Afatinib Completed
  15. Phase 1 Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects Completed
  16. Phase 1 Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. Completed
  17. Phase 1 Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) Completed
  18. Phase 1 Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib Completed
  19. N/A The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer Completed
  20. N/A Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma Completed
  21. N/A Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. Completed
  22. N/A Afatinib Osimertinib Sequencing NIS Completed
  23. N/A GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations Completed
  24. N/A A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel Completed
  25. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed
  26. N/A Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Genetics & Precision Medicine Phase I
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
May 1, 2026